MRNA Moderna Inc

1.36 (1.38%)
Last Updated: 12:48:12
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 1,419,239
Bid Price 99.48
Ask Price 99.57
News -
Day High 99.6199


52 Week Range


Day Low 97.89
Company Name Stock Ticker Symbol Market Type
Moderna Inc MRNA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.36 1.38% 99.525 12:48:12
Open Price Low Price High Price Close Price Prev Close
98.57 97.89 99.6199 98.17
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
23,036 1,419,239 $ 98.75 $ 140,150,243 - 95.02 - 217.25
Last Trade Time Type Quantity Stock Price Currency
12:48:12 100 $ 99.525 USD

Moderna (MRNA) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Moderna Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
37.88B 380.59M - 19.26B 8.36B 21.97 4.53
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Moderna News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MRNA Message Board. Create One! See More Posts on MRNA Message Board See More Message Board Posts

Historical MRNA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week102.31107.7997.11102.163,078,729-2.79-2.72%
1 Month113.75118.0797.11108.413,863,298-14.23-12.51%
3 Months122.89128.9895.02111.593,984,493-23.37-19.01%
6 Months149.80163.2495.02123.063,585,215-50.28-33.56%
1 Year123.34217.2595.02147.164,102,459-23.82-19.31%
3 Years69.53497.1765.4899202.489,099,11030.0043.14%
5 Years22.00497.1711.54149.368,743,39677.53352.39%

Moderna Description

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.